Thomas LEMARCHAND

En résumé

Entreprises

• TPL Path Labs - Chief Scientific Officer

  2016 - maintenant Assure le développement de nouveaux biomarqueurs et essais et plus généralement les orientation et la qualité scientifique de TPL Path Labs

• Covance - Senior Pathologist

  Princeton 2014 - 2016 Pathologie expérimentale dans les études de sécurité des nouveaux produits

• Sciempath Sarl - Service et Consult. en Path. Invest. Exp. Mol. et Tox. - Associé/Partner

  2012 - 2014 Consultant en Pathologie expérimentale, toxicologique et moléculaire et en biomarqueurs. Spécialiste des médicaments issus des biotechnologies. Expérience en biomarqueurs in situ, immunologie, génomique, ELISA, tests multiplex, biomarqueurs sur biofluides, études de réactivité croisée tissulaire, validation de cible, pathologie toxicologique, pathologie expérimentale et investigative, thérapie cellulaire, analyse d'image.

• CIT (Now Citoxlab France) - Senior Pathologist and Head of Clinical and Molecular Pathology

  2007 - 2011 2/2011-11/2011 Citoxlab France, Miserey, France, Contract Research Organisation (CRO) – Head of Biomarker Department
  Responsibilities included:
  1. Development and validation of biomarker and immunology assays: ELISA and Luminex, flow cytometry (biomarkers and therapeutic antibody cross reactivity), non-standard clin. path. assays, ELISPOT assays, rat kidney biomarker panels, implementation of in situ hybridization (ISH).
  2. GLP study director (SD) and reader/peer review (PR) pathologist in Tissue Cross Reactivity (TCR) studies.
  3. Scientific and Business Adviser in molecular pathology and biomarkers.
  4. Management of 3 scientists and 2 MSc trainees. Training of 2 pathologists in Molecular Pathology.
  
  2010-2011 CIT – Head of Molecular and Clinical Pathology
  Responsible of biomarker development at CIT.
  Responsibilities included:
  1. Leading novel developments in biomarker, acid nucleic assays and molecular pathology areas (including fluorescence and confocal microscopy)
  2. TCR project leader, business support, SD and reader/PR pathologist.
  2. Management and business support of genomic department, binding assays and clinical pathology laboratories (4 direct reports - 3 Scientists and 1 Lab Manager).
  3. Special projects in neuropathology (developmental neuropathology and neurovirulence asessment of vaccines).
  4. Training of one pathologist colleague as a backup in TCR and IHC and a DESV 3rd year trainee.
  
  2007-2009 Senior Pathologist
  1. Responsible for reading and peer-reviewing non-clinical toxicology studies
  2. Implementation of Tissue Cross Reactivity service for novel therapeutic monoclonal antibodies for human diseases.
  3. Development of novel immunohistochemistry (IHC) biomarkers.
  4. GLP-qualification of Discovery XT automatic IHC apparatus. GLP-validation of MorphoExpert from Explora-Nova (Image Analysis).

• Eli Lilly and Company - Senior Research Scientist, Toxicologic Pathology

  neuilly sur seine 2003 - 2006 ELI LILLY & CO. – Lilly Development Centre SA, Mont-Saint-Guibert, Belgium
  Senior Research Scientist, Pathology and
  Interim Supervisor of the pathology and clinical pathology laboratories (May 2005-December 2006)
  · Project pathologist for Lead Optimization toxicology and investigative studies performed under Good Research Practices conditions
  · Supervision of the histology laboratory and investigative work.
  · Maintained quality and timeliness as Interim Supervisor of the Anatomic and Clinical Pathology laboratories
  · Worked with project teams for early resolution of toxicology issues spanning several chemical platforms.
  · Worked with the Metabonomics Laboratory to develop methods to improve sensitivity and specificity of detecting target organ toxicity where histopathology is relatively insensitive
  · Worked to develop the use of immunohistochemistry (IHC) to characterize the metabolic enzyme levels to accelerate discovery profiling in preclinical species (rat) and other endpoints (glutathione levels, apoptosis), including the use of Image Analysis (Zeiss’ KS400® and Olympus’ AnalySIS® softwares).
  · Member of a multidisciplinary academic /Lilly group to characterize new models of neurodegenerative diseases.

• Biologie Servier - Toxicologic Pathologist

  2001 - 2003 SERVIER R&D Toxicological Centre – Biologie Servier S.a.r.l., Gidy, France
  Toxicologic Pathologist
  · Study pathologist of non-clinical GLP and non-GLP safety studies. Prepared pathology reports submitted to the EMEA.
  · Responsible for the electron microscopy laboratory including preparation and maintenance of SOPs and improvement of instrumentation, interpretation, and reporting procedures.
  · Responsible for protocol development for pathology portions of toxicology studies in cooperation with the Study Director
  · Developed knowledge in new drug development strategies and compound management

Formations

• Louisiana State University - School Of Veterinary Medicine LSU-SVM (Baton Rouge)

  Baton Rouge 1995 - 2000 Immunopathology
  
  Prestation de service en pathologie diagnostique pour le Vet Teaching Hospital
  
  Graduate School - Veterinary Sciences - Thèse de troisième cycle sur la lèpre et le virus de l'immmunodéficience simienne (SIV)- Maître de thèse: Dr Scollard

• Ecole Nationale Vétérinaire

  Nantes 1986 - 1990 Formation générale + Pathologie
  
  Résident en pathologie vétérinaire de 1990 à 1992

Réseau

• André ESSAHLI

• Christophe VOCAT

• Clarisse MINOIS

• Damien GUYOMAR

• Fabrice TAUSCHER

• Jean Marc PAVARD

• Michèle LOEFFLER

• Olivier CARIOU

• Pierre SERFASS

• Régis MASSON